Skip to main content
. Author manuscript; available in PMC: 2013 Sep 11.
Published in final edited form as: Vaccine. 2012 Apr 3;30(26):3937–3943. doi: 10.1016/j.vaccine.2012.03.071

Figure 2.

Figure 2

Predicted probability using logistic regression models for seroprotection (hemaglutination inhibition titer ≥40) for either age or modified Vulnerable Elders Survey (VES-13) score for the H1N1 and H3N2 vaccine strains. The model controlled for gender, age, body mass index (BMI), VES13 score, and pre-vaccination HAI titers. Seroprotection for influenza B was not analyzed due to almost complete seroconversion in this population for this vaccine strain.